Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:38:59 2024-04-24 am EDT			5-day change	1st Jan Change
87.7 ^EUR	-1.29%		+1.76%	-2.30%

Apr. 24	SANOFI : Bernstein remains its Buy rating	ZD
Apr. 24	Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff	MT

Sanofi : Correction to the Drug Pricing Article

May 21, 2020 at 05:12 pm EDT

The Institute for Clinical and Economic Review has led the way in recommending drug prices based on effectiveness, and the National Institutes of Health helped design Moderna's vaccine. "Coronavirus Revives Debate Over Drug Pricing," at 1:49 p.m. ET, incorrectly stated the Institute for Clinical Economic Review and the National Institutes for Health.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ASTRAZENECA PLC	11,352 GBX	+0.75%	+4.51%	217B
JOHNSON & JOHNSON	148.5 USD	-0.69%	+2.60%	360B
MODERNA, INC.	108.8 USD	+0.89%	+5.23%	41.31B
GILEAD SCIENCES, INC.	67.08 USD	+0.07%	+0.22%	83.58B

Latest news about Sanofi

SANOFI : Bernstein remains its Buy rating	Apr. 24	ZD
Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff	Apr. 24	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 23	MT
Sector Update: Health Care	Apr. 23	MT
Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business	Apr. 23	MT
Sanofi Is Said To Ask Banks To Pitch For $20 Billion OTC Spinoff - Bloomberg News	Apr. 23	RE
CAC40: up sharply, back over 8100 pts	Apr. 23	CF
CAC40: back to 8100, E-Stoxx to 5000, Nasdaq +1.5	Apr. 23	CF
CAC40: closes in on 8,100, well supported by W-Street	Apr. 23	CF
CAC40: up slightly after encouraging PMI figures	Apr. 23	CF
Sanofi: positive phase III data in IPT	Apr. 23	CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia	Apr. 23	MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial	Apr. 23	DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims	Apr. 23	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team	Apr. 22	MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer	Apr. 22	MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million	Apr. 22	MT
SANOFI : Gets a Buy rating from UBS	Apr. 22	ZD
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Global markets live: P&G, Amex, Blackstone, Apple, Tesla...	Apr. 19
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 19	MT

Chart Sanofi

Duration

Period

More charts

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

01:30am - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

87.7 EUR

Average target price

107.8 EUR

Spread / Average Target

+22.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-2.30%	119B
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Sanofi : Correction to the Drug Pricing Article

Stocks mentioned in the article

EPS Revisions